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Abstract 6 
The neurotransmitter serotonin has been widely implicated in the pathophysiology of major 7 
depressive disorder (MDD). In animal studies and human neuroimaging studies, involvement of 8 
the serotonin receptor 1B (5-HT1BR) in MDD and memory performance has been reported. 9 
However, the role of the 5-HT1BR in cognitive functions affected in MDD remains to be 10 
clarified. Ten patients with MDD diagnosis were examined with positron emission tomography 11 
(PET) and a battery of cognitive tests before and after Internet-based Cognitive Behavioral 12 
Therapy (ICBT). The results were compared to ten matched control subjects in order to 13 
investigate putative changes in 5-HT1BR availability and cognitive performance. Patients treated 14 
with ICBT showed statistically significant improvement relative to baseline in Verbal fluency, 15 
both letter and category production. Significant correlations were found between improvement in 16 
letter production and changes in 5-HT1BR availability in ventral striatum, between category 17 
production and amygdala, as well as between the improvement in Trailmaking test B and change 18 
in 5-HT1BR binding in dorsal brainstem, in amygdala and in hippocampus. The results suggest 19 
an association between 5-HT1BR binding and improvement in cognitive functioning. 20 
Replications in larger-scale studies are required to confirm these findings.  21 
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1. Introduction  40 
Major depressive disorder (MDD) has a lifetime prevalence of 11-15 % (Bromet et al., 41 
2011) and is the leading cause of disability worldwide (World Health Organization, 2017). It is a 42 
clinically heterogeneous disease of variable course in which the core symptoms, low mood and 43 
loss of interest, are related to emotional dysregulation. Recent research has demonstrated that also 44 
cognitive impairments play an important role in the symptomatology of MDD (Rock et al., 2014; 45 
Trivedi and Greer, 2014). These include reversible dysfunctions that largely normalize after a 46 
major depressive episode, that is, visuospatial short term memory function (Behnken et al., 47 
2010), and persistent cognitive impairments remaining after remission, such as attention and 48 
executive functions (Rock et al., 2014; Årdal and Hammar, 2011). In a meta-analysis 49 
investigating executive function in 375 depressed patients and 481 control subjects, patients were 50 
found to perform significantly worse in tasks measuring semantic verbal fluency, cognitive 51 
flexibility and impulse inhibition (Wagner et al., 2012). Clinically significant impairments in 52 
several cognitive domains including psychomotor speed, attention, visual learning and memory, 53 
and executive functions have repeatedly been shown to be associated with MDD (Gallagher et 54 
al., 2007; Marazziti et al., 2010; Trivedi and Greer, 2014).  55 
As the biological underpinning of MDD is largely unknown, so are the biological 56 
mechanisms mediating the cognitive deficits in MDD. Of the various hypotheses for MDD, the 57 
monoamine deficiency hypothesis is the most investigated (Agurell, 1981; Coppen, 1967). The 58 
monoaminergic hypothesis is mainly based on observations of clinical effects of antidepressant 59 
drugs. The currently most widely used pharmacological treatment for MDD is selective serotonin 60 
reuptake inhibitors (SSRIs), which inhibit the serotonin transporter and modify serotonin 61 
concentration in the synaptic cleft (Lundberg et al., 2007; Nord et al., 2013; Romero et al., 1996). 62 
Additional support for an association between serotonin and depression comes from tryptophan 63 
depletion studies showing that acute tryptophan depletion results in increased depressive 64 
symptoms in remitted MDD patients and subjects with a family history of MDD (Ruhé et al., 65 
2007).  66 
To date, 14 different receptor subtypes for serotonin have been identified in the mammalian 67 
brain. With molecular positron emission tomography (PET), specific receptor and transporter 68 
proteins can be quantified in the living human brain. In a majority of PET studies of the serotonin 69 
system in patients with MDD, differences in 5-HT1A receptor as well as serotonin transporter 70 
binding compared to control subjects have been found (Gryglewski et al., 2014; Savitz and 71 
Drevets, 2013). The serotonin receptor 1B (5-HT1BR) has only recently been investigated in 72 
MDD. As a heteroreceptor it regulates the release of neurotransmitters such as dopamine or 73 
GABA. As an autoreceptor it is involved in the negative feedback mechanism that controls the 74 
release of serotonin (Celada et al., 2013; Ruf and Bhagwagar, 2009). Preclinical studies indicate a 75 
role of the 5-HT1BR in various behavioral functions such as locomotor activity and aggression 76 
(Ramboz et al., 1996), sleep (Boutrel et al., 1999), learning (Wolff et al., 2003) and learned 77 
helplessness (McDevitt et al., 2011).  78 
Human in vivo studies of the 5-HT1BR have been scarce, but with PET and the 5-HT1BR 79 
radioligand [11C]AZ10419369 correlations have been shown between [11C]AZ10419369 binding 80 
in grey matter and creativity fluency both in control subjects and in patients with Parkinson 81 
Disease (Varrone et al., 2015). In a study of aggression, a positive correlation was found between 82 
trait anger and serotonin 1B receptor binding in striatum (da Cunha-Bang et al., 2016). Also, 83 
differences in 5-HT1BR binding have been reported after psychotherapy in depressed patients 84 
(Tiger et al., 2014) as well as in comparison to a control group (Murrough et al., 2011; Tiger et 85 
al., 2016). Taken together, recent research in both animals and humans suggest a role for 5-86 
HT1BR in several aspects of cognitive function and personality, and in the pathophysiology of 87 
MDD. Nevertheless, the relation between cognitive changes in MDD and 5-HT1BR binding still 88 
remains to be characterized. The limited success of research on the biological underpinning of 89 
MDD has raised questions concerning the definition of biologically relevant phenotypes. 90 
Cognitive functions affected in mood disorder has been suggested as examples of intermediate 91 
phenotypes more robustly related to biological markers (Hasler et al., 2004). This study was thus 92 
designed to explore cognitive domains impaired in MDD and their 93 
relation with [11C]AZ10419369 binding.  94 
The aim of this exploratory study was to investigate potential associations between changes 95 
in cognitive performance in depression and 5-HT1BR binding, assessed using standardized 96 
cognitive tests, positron emission tomography and the radioligand [11C]AZ10419369 in a group 97 
of depressed patients before and after treatment with psychotherapy as well as in comparison to 98 
matched control subjects.  99 
 100 
2. Material and methods  101 
The study was approved by the regional Ethical Review Board in Stockholm, by the 102 
Radiation Safety Committee of the Karolinska University Hospital and was carried out in 103 
accordance with the Declaration of Helsinki. Written informed consent was obtained from all 104 
subjects before participation.  105 
 106 
2.1. Recruitment of patients 107 
Ten adult patients with untreated MDD of moderate type (Montgomery Åsberg Depression 108 
Rating Scale (MADRS) scores 20-35) according to Diagnostic and Statistical Manual of mental 109 
disorders (DSM-IV) were recruited by advertisements in press or by the unit of Internet 110 
Psychiatry (IPU) at Psychiatry Southwest, Karolinska University Hospital, Southern Campus in 111 
Stockholm, Sweden (Tiger et al., 2014). The diagnosis was assessed by a psychiatrist using the 112 
Mini International Neuropsychiatric Interview (MINI). Inclusion criteria were healthy according 113 
to medical history, physical examination, blood analysis and magnetic resonance imaging (MRI). 114 
Exclusion criteria were: bipolar disorder, current substance abuse, organic brain disorder, 115 
pregnancy, current psychopharmacological treatment or MRI abnormalities. Control subjects 116 
were recruited by newspaper advertisement or from a website designed for scientific research 117 
volunteers. The group consisted of ten healthy participants according to psychiatric history and 118 
interviews with MINI or the Structured Clinical Interview for the Diagnostic and Statistical 119 
Manual of Mental Disorders (fourth edition) (for details, see Tiger et al., 2016). They were 120 
matching the patients regarding gender and age (±3 years (±4 years for one pair); table 1). The 121 
PET data in the current study was drawn from previous studies (Tiger et al., 2016, 2014).  122 
 123 
2.2. Study design 124 
Each subject underwent an MRI examination, a PET experiment and a battery of cognitive 125 
tests within two weeks after the MRI scan. PET examinations were performed on the same day or 126 
the day before the cognitive testing. For the patients, Internet-based cognitive behavioral therapy 127 
(ICBT) was initiated on the same day as the first PET experiment (treatment duration 11.9 ±1.4 128 
weeks), conducted in a routine care setting at the IPU. For the patients, a second PET experiment 129 
and set of cognitive tests followed 14±2.2 weeks after treatment initiation. Clinician-rated 130 
MADRS was administered at each time of PET (mean score at baseline was 26 and mean score at 131 
follow-up was 7.4). Also, self-rated MADRS-S was completed by the patients every week 132 
throughout the study. The control subjects did not receive ICBT, but only a second assessment 133 
consisting of cognitive testing followed approximately 12 weeks after the first examination. 134 
Urine toxicology tests were executed on the day of each PET examination and were negative. 135 
The results of the PET experiments in relation to MDD have previously been reported (Tiger et 136 
al., 2016, 2014). 137 
 138 
2.2.1. Psychological treatment 139 
The psychological approach of cognitive behavioral therapy (CBT) refers to a set of 140 
interventions focusing on maladaptive cognitions, behaviors and emotions. The treatment 141 
consists of different modules and techniques, such as cognitive restructuring or behavioral 142 
activation, to decrease symptoms and increase level of functioning. Internet-based CBT (ICBT) is 143 
based on traditional face-to-face CBT protocol but is delivered online with guidance from a 144 
therapist via the platform (Hedman et al., 2012). Every week, the patient receives a new module 145 
with information, questions relevant to the disorder and homework assignments to complete. 146 
 147 
2.3. Assessment of cognitive performance 148 
Cognitive functioning was examined in all subjects on two occasions. The tests were 149 
selected to measure cognitive functions specifically affected in MDD (Blanco et al., 2013; Rock 150 
et al., 2014; Snyder, 2013). Visuo-constructive memory ability was assessed with Rey Complex 151 
Figure Test (RCFT) (Shin et al., 2006) at baseline and Taylor Complex Figure Test (TCFT) at 152 
follow-up in order to minimize learning effects. Executive functions were assessed with the 153 
subtests letter production and category production in Verbal Fluency (Tombaugh et al., 1999) as 154 
well as Trailmaking Test (TMT) A and B (Kortte et al., 2002). General intellectual ability was 155 
estimated by the subtest Vocabulary in Wechsler Adult Intelligence Scale, third version (WAIS-156 
III).  157 
 158 
2.4. Image acquisition and analysis 159 
All subjects underwent MRI; Signa 1.5T or 3.0T, GE Healthcare, for exclusion of brain 160 
pathology and co-registration with PET data. An individual head fixation system was used during 161 
PET measurements (Bergström et al., 1981). Each patient was examined twice with PET; ECAT 162 
High Resolution Research Tomograph (HRRT, Siemens Molecular Imaging) and the radioligand 163 
[11C]AZ10419369 (injected radioactivity: 385.7 ± 30.9 MBq). Brain radioactivity in each PET 164 
examination was measured during 93 minutes with a frame sequences ranging from 20 seconds to 165 
six minutes. SPM5 (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging, 166 
U.K.) was used to co-register T1-weighted (T1-w) MRI images to PET images and to segment 167 
MRI images. Regions of interest (ROI) were defined according to previous studies (Tiger et al., 168 
2016, 2014) and chosen based on previous literature showing abnormal serotonin marker 169 
densities in MDD (Drevets, 2000; Murrough et al., 2011; Savitz and Drevets, 2013): orbitofrontal 170 
cortex (OFC), anterior cingulate cortex (ACC), subgenual prefrontal cortex (SPC), amygdala, 171 
hippocampus (both dorsal and ventral sub regions), ventral striatum and dorsal brainstem (DBS), 172 
and for reference cerebellum. The ROIs were defined manually on individual MRI images, and 173 
later on, transferred into PET images (Varnäs et al., 2011). Binding potential (BPND) was 174 
quantified by the stationary wavelet transform-based parametric mapping framework (S-WAPI) 175 
implemented in Matlab R2007b for Windows (Cselényi et al., 2006; Schain et al., 2013; 176 
Turkheimer et al., 2003). The cerebellum was chosen as reference region due to its negligible 5-177 
HT1BR density (Table 3) (Tiger et al., 2016, 2014; Varnäs et al., 2001). 178 
 179 
2.5. Statistics 180 
Paired samples t-tests were applied to compare the results of cognitive performance, and 5-181 
HT1BR binding between the two groups and pre-/post- treatment. Effects of diagnostic group and 182 
test occasion on cognitive performance were analyzed by a mixed effects modelling approach for 183 
repeated measures, as this allows accommodating missing data and the integration of time-184 
varying factors. Group and time were considered as fixed effects in the model. Cognitive 185 
performance and 5-HT1BR binding was related using Pearson’s correlation coefficients. For 186 
correlations found to be significant in the initial analyses, hierarchical multiple regression models 187 
were applied for each group and time point of examination by using each significant cognitive 188 
test result as a dependent variable and age, educational level as well as BPND for each significant 189 
ROI as predictors. In order to explore the relationship between differences in cognitive 190 
performance and differences in 5-HT1BR binding, the relative change in cognitive performance 191 
and 5-HT1BR binding between baseline and follow-up (cognitive performance follow-up – 192 
cognitive performance baseline)/cognitive performance baseline=∆CP; (BPND follow-up – BPND 193 
baseline)/BPND baseline=∆BPND) as well as between differences in cognitive performance (∆CP) 194 
and clinical change using MADRS (MADRS score follow-up – MADRS score baseline/MADRS 195 
score baseline=∆MADRS) was examined by Pearson’s correlation coefficient. All statistical 196 
analyses were conducted using SPSS (version 23) for Windows with alpha set at 0.05 (two-197 
tailed).    198 
 199 
3. Results 200 
The patients were examined twice with PET and all participants were examined twice 201 
regarding cognitive testing. Unfortunately, due to missing data, part of the cognitive test results 202 
could not be retrieved (Table 2). There were no statistically significant differences in age, global 203 
IQ or education between the groups (Table 1 and 2).  204 
 205 
3.1. Cognitive performance at baseline and follow-up 206 
In the patient group, paired samples t-test revealed a significant improvement from baseline 207 
to follow-up in Verbal fluency, both regarding letter (t=-3.14; p=0.02) and category production 208 
(t=-2.66; p=0.038), but not in RCFT/TCFT, TMT A or TMT B. In the control group, there was a 209 
significant improvement from baseline to follow-up in category production (t=-2.76; p=0.04), but 210 
no significant performance differences in letter production, RCFT/TCFT, TMT A or TMT B.  211 
 212 
3.2. Associations between cognitive performance and 5-HT1BR binding    213 
In the patient group at baseline, Pearson´s correlation coefficient showed a moderate 214 
correlation between delayed recall in RCFT and 5-HT1BR binding in the amygdala (r=0.65; 215 
p=0.041), ventral striatum (r=0.69; p=0.027) and DBS (r=0.69; p=0.028). A moderate correlation 216 
was also found between delayed recognition in RCFT and 5-HT1BR binding in amygdala 217 
(r=0.66; p=0.04), ventral striatum (r=0.71; p=0.022) and DBS (r=0.74; p=0.015). No significant 218 
correlations between cognitive performance and 5-HT1BR binding were found in the patient 219 
group at follow-up (p>0.05).  220 
To control for effect of age and educational level on the observed association between 221 
cognitive performance and BPND, multiple linear regression analyses were undertaken using 222 
cognitive test score as a dependent variable and age, educational level as well as regional BPND as 223 
predictors. For the patients at baseline, there were no significant effects of any of the predictors 224 
on RCFT, delayed recall. 225 
In the control group at baseline, there were strong correlations between delayed recall in 226 
RCFT and 5-HT1BR binding in the OFC (r=0.89; p=0.003) and amygdala (r=0.81; p=0.015). A 227 
strong correlation was also found in delayed recognition in RCFT and 5-HT1BR binding in the 228 
OFC (r=0.96; p=0.001) and DBS (r=0.83; p=0.021). For other cognitive domains tested, 229 
correlations between performance and 5-HT1BR binding were not statistically significant 230 
(Supplementary table).  231 
When using multiple linear regression and controlling for age and educational level, the 232 
relationship between RCFT, delayed recognition and 5-HT1BR binding in DBS remained 233 
statistically significant in multiple regression analyses correcting for the effects of age and 234 
educational level (β=10.62; p=0.026). Furthermore, the effect of age on RCFT, delayed 235 
recognition was found to be statistically significant (β=-0.30; p=0.013).  236 
 237 
3.3. Group differences in cognitive performance at baseline 238 
In RCFT delayed recognition, patients performed significantly better than controls (t=3.62; 239 
p=0.011).    240 
 241 
3.4. Group differences in cognitive performance at follow-up 242 
In Verbal fluency subtest letter production, patients performed significantly better than the 243 
control subjects (t=8.14; p=0.001). There were no significant differences in general intellectual 244 
ability estimated with WAIS-III Vocabulary task.  245 
 246 
3.5. Effect of time and group on cognitive performance 247 
A linear mixed-effect model analysis revealed significant effect of time on the performance 248 
in RCFT and TCFT, delayed recognition (F(1, 26) =6.96, p=0.014), an effect of group on the 249 
performance in letter production (F(1, 28) =7.84, p= 0.009) as well as effect of time on category 250 
production (F(1, 28) =6.11, p=0.02). No significant interaction effects (time*group) were shown 251 
(p>0.05).  252 
 253 
3.6. Difference in cognitive performance and 5-HT1BR binding before and after treatment 254 
To examine whether differences in cognitive performance correlated with differences in 5-255 
HT1BR binding between baseline and follow-up in the patient group, the relative change (∆CP 256 
and ∆BPND, respectively) in each cognitive test result as well as 5-HT1BR binding in each ROI 257 
were calculated. Pearson’s correlation coefficients revealed significant positive correlations 258 
between the improvement in letter production and difference in 5-HT1BR binding in ventral 259 
striatum (r=0.79; p=0.033), in category production and amygdala (r=0.76; p=0.049) as well as 260 
between the improvement in TMT B and difference in 5-HT1BR binding in DBS (r=0.85; 261 
p=0.032), in amygdala (r=0.87; p=0.024) and in hippocampus (r=0.89; p=0.017; Table 4).  262 
 263 
3.7. Difference in cognitive performance and clinical change before and after treatment 264 
Within the patient group, Pearson´s correlation coefficient revealed no significant 265 
correlations (p<0.05) between difference in cognitive performance (∆CP) and difference in 266 
clinical change (∆MADRS) between baseline and follow-up. 267 
 268 
4. Discussion  269 
Previous research in animal models, healthy volunteers and MDD patients suggests a role 270 
for 5-HT1BR in major depressive disorder and cognition. For instance, studies show 5-HT1BR 271 
binding reduction in DBS (Tiger et al., 2014), ACC, SGPFC and hippocampus (Tiger et al., 272 
2016) as well as in ventral striatum/ventral pallidum (Murrough et al., 2011). In this exploratory 273 
study, the relation between cognitive performance in tests sensitive to MDD and 5-HT1BR 274 
binding in brain regions suggested to be involved in the pathophysiology of MDD have been 275 
investigated.  276 
The result indicates that MDD patients improved in cognitive functioning at follow-up, and 277 
that this improvement in cognitive performance was positively correlated to changes in 5-HT1BR 278 
binding. In the patient group, improvement in letter and category production had a strong and 279 
positive correlation with changes in 5-HT1BR binding in ventral striatum and in amygdala, 280 
respectively. Further on, improvement in TMT B was positively correlated to changes in 5-281 
HT1BR binding in the DBS, amygdala, and hippocampus. However, performance in category 282 
production improved in both the patient group and control group, indicating a learning effect in 283 
this task.   284 
Verbal fluency is a task considered to be sensitive to sustained attention, processing speed, 285 
and memory retrieval (Badre et al., 2014; Fossati P, Guillaume le B, Ergis AM, 2003), that is, 286 
cognitive functions well known to be impaired in MDD. The molecular mechanisms mediating 287 
verbal fluency and associated cognitive functions are not known in detail. However, verbal 288 
fluency is known to correlate with idea fluency, a test previously shown to predict 5-HT1BR 289 
binding in average grey matter of control subjects and patients with Parkinson´s disease (Silvia et 290 
al., 2013; Varrone et al., 2015). In a recent fMRI study, activation of the ventral striatum was 291 
reported to be related to learning and success of memory retrieval strategies (Badre et al., 2014). 292 
Although the current study was designed to identify variability over a longer time span, the 293 
finding that changes in 5-HT1BR binding in the ventral striatum and in amygdala is associated 294 
with improvement in letter and category fluency, taken together with previous data on 5-HT1BR 295 
and idea fluency suggests that the serotonin system may have a role in mediating aspects of 296 
verbal fluency function.  297 
  TMT B measures spatial navigation, sustained attention, psychomotor speed and 298 
executive function (Gould et al., 2007; Kortte et al., 2002; Porter et al., 2003; Snyder, 2013), 299 
domains known to be impaired in MDD (Rock et al., 2014; Wagner et al., 2012). Serotonin has 300 
been suggested to be mediating these symptoms, as for instance improvement in psychomotor 301 
speed is a known effect from successful treatment of MDD using SSRIs (Blier et al., 1990; 302 
Rosenblat et al., 2015). The DBS encloses a major part of the rostral raphe nuclei where the 303 
largest group of serotonergic neurons within CNS are situated, making it a key region for 304 
regulation of serotonin transmission, that is, decreased 5-HT1BR binding in DBS may reflect 305 
globally increased serotonergic activity affecting cognitive functions measured with TMT B. 306 
Regarding the amygdala, it has been shown in meta-analyses of fMRI research that the amygdala 307 
of patients with affective disorder is more activated during a task measuring sustained attention 308 
compared to controls (Sepede et al., 2014). Rumination, an activity negatively associated with 309 
sustained attention, has been shown to be positively associated to increased amygdala reactivity 310 
as well as abnormal metabolic activity in the hippocampus in MDD subjects (Mandell et al., 311 
2014). Taken together, the findings suggest that the improved cognitive function related to MDD 312 
at baseline and follow-up may be connected to reduced 5-HT1BR binding in limbic structures, 313 
such as DBS, amygdala and the hippocampus.  314 
In the patient group, both letter and category production improved significantly. These are 315 
both measures of the executive function domain and examine sustained attention, concentration, 316 
retrieval and speed. Several studies show that the domain of executive function is related to MDD 317 
(Gallagher et al., 2007; Wagner et al., 2012). The finding of improved letter production in the 318 
patient group is in agreement with previous larger non-imaging studies on MDD and cognition, 319 
thus confirming the validity of the cognitive performance results (Biringer et al., 2007; Gallagher 320 
et al., 2007; Lee et al., 2012). However, as there was no interaction effect of group and time for 321 
any of the tests, a learning effect cannot be excluded, hence, these results suggest caution in the 322 
interpretation of the findings.  323 
In contrast to previous literature, the present results show that cognitive performance was 324 
superior in MDD patients compared to control subjects (Table 2). Previously identified factors 325 
explaining this could be the (albeit non-significant) difference in age (Lei et al., 2014; Watanabe 326 
et al., 2005), level of education (Grant et al., 2001; Lee et al., 2012) and occupational status 327 
(Wang et al., 2006) as well as the relatively small sample size compared to previous studies of 328 
cognitive performance in MDD not including molecular imaging (Lei et al., 2014; Wang et al., 329 
2006).  330 
The present study has a number of limitations. Even though the sample size may be 331 
reasonable for molecular imaging studies, it is smaller than in most neuropsychological studies 332 
(Quinn et al., 2012). Moreover, the study has suffered data loss. Both these factors increase the 333 
risk of type-II errors and all conclusions, although novel should therefore be seen as preliminary 334 
until replicated. It cannot be ruled out that the correlations between cognitive performance and 5-335 
HT1BR binding in 3.2 in part may be driven by age, as an age effect previously has been reported 336 
(Nord et al 2014). Lastly, variations regarding the time aspect may have influenced the results, as 337 
a diurnal variability in binding to serotonin markers has been reported (Matheson et al., 2015). 338 
Notably, as is evident from Table 4, the significant findings reported were not corrected for 339 
multiple comparisons, and should thus be seen as hypothesis generating.  340 
In conclusion, the study indicates a possible association between 5HT1BR binding and 341 
cognitive performance in MDD. Future large-scale investigations are required to confirm these 342 
findings. Importantly, the results support the feasibility of combining rigorous cognitive 343 
performance quantification with molecular imaging pre- and post a therapeutic intervention in 344 
order to disentangle putative translational biomarkers of psychiatric disease. 345 
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Table 1 
Patient and matched control subject characteristics  
Patients  Matched controls 
 Nr  Age Gender Education Hand Episodes MADRS  Age Gender Education 
1  25 Male 13 Right 2 20  29 Male 15 
2  51 Female 17 Right 10 35  54 Female 13,5 
3  46 Female 15 Right 3 28  46 Female 20 
4  68 Female 16 Right 3 24  69 Female 7 
5  66 Male 19 Right 3 28  64 Male 15 
6  37 Female 15.5 Right >10 26  36 Female 18 
7  66 Male 16.5 Right >10 25  69 Male 13 
8  24 Female 14 Right 3 26  25 Female 16 
9  57 Male 20 Right 2 24  54 Male 13 
10  38 Female 18 Right 2 24  41 Female 15 
M  47.8  16.4   26  48.7  14.6 
SD ±16.97  ±2.2   ±3.9  ±16.0  ±3.5 
Note. Education = years of education; Hand= handedness; Episodes= number of major depressive episodes; MADRS = Montgomery Åsberg Depression Rating Scale at baseline; 








Results for the different subjects in RCFT/TCFT (Rey´s Complex Figure Test, Taylor´s Complex Figure Test), Verbal fluency letter and category production, TMT A and B 
(Trailmaking Test) and WAIS-III (Wechsler Adult Intelligence Scale, version III) 
 Controls   Patients 
 Baseline  Follow-up   Baseline  Follow-up  






















































WAIS-III  - 46.5 (9.4)
8 
  - 49.0 (6.8)
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Correlations (r) between the difference in cognitive test performance and difference in BPND in the patient group 
 ∆TCFT/RCFT, delayed 
recall r (p) 
∆TCFT/RCFT, delayed 
recognition r (p) 
∆Letter 
production r (p) 
∆Category 
production r (p) 
 
∆TMT A r (p) 
 
∆TMT B r (p) 
∆OFC   0.40 (0.38)   0.28 (0.54)  0.53 (0.22) 0.46 (0.30) -0.19 (0.69) 0.53 (0.28) 
∆ACC   0.31 (0.50)   0.23 (0.63)  0.37 (0.42) 0.26 (0.57) -0.60 (0.15) 0.40 (0.44) 
∆SPC -0.05 (0.91) -0.14 (0.77) 0.02 (0.97) 0.24 (0.61) -0.13 (0.78) 0.15 (0.78) 
∆VST  0.48 (0.28)   0.40 (0.37)    0.79 (0.03)* 0.50 (0.26) -0.28 (0.55) 0.38 (0.46) 
∆AMY  0.74 (0.06)   0.61 (0.15)  0.40 (0.37)    0.76 (0.05) *  0.33 (0.47)   0.87 (0.02)* 
∆HIP 0.58 (0.17)  0.45 (0.31)  0.24 (0.60) 0.42 (0.35)  0.10 (0.83)    0.89 (0.02)* 
∆DBS 0.44 (0.32)  0.24 (0.60) 0.19 (0.69) 0.36 (0.43) -0.04 (0.93)    0.85 (0.03)* 
Note. RCFT=Rey´s Complex Figure Test; TCFT=Taylor´s Complex Figure Test; TMT A= Trailmaking test A; TMT B= Trailmaking test B; ACC=anterior 
cingulate cortex; OFC=orbitofrontal cortex; SPC=subgenual prefrontal cortex; VST= ventral striatum; DBS=dorsal brainstem; AMY=amygdala; 





Mean [11C]AZ10419369 binding 
 Controls BPND ±SD Patients BPND ±SD (PET1) Patients BPND ±SD (PET2) Change in BPND ((PET2-
PET1)/PET2) 
OFC 1.08 ± 0.16 0.99 ± 0.36 0.93 ± 0.23 -0.05 ± 0.17 
ACC 1.03 ± 0.25 0.80 ± 0.27 0.81 ± 0.18 0.01 ± 0.21 
SPC 0.90 ± 0.11 0.71 ± 0.24 0.74 ± 0.19 0.05 ± 0.17 
Ventral striatum 2.03 ± 0.40 1.79 ± 0.43 1.71 ± 0.31 -0.05 ± 0.20 
Amygdala 0.91 ± 0.20 0.81 ± 0.38 0.73 ± 0.26 -0.15 ± 0.47 
Hippocampus 0.33 ± 0.12 0.26 ± 0.12 0.21 ± 0.10 -0.31 ± 0.53 
DBS 0.45 ± 0.28 0.56 ± 0.25 0.38 ± 0.20 -0.76 ± 1.02 
Note. BPND = binding potential; SD= standard deviation; PET= positron emission tomography; OFC=orbitofrontal cortex; ACC=anterior cingulate cortex; 
SPC=subgenual prefrontal cortex; DBS=dorsal brainstem.  
Supplementary table 
Pearson´s correlations (rxy) between cognitive performance and 5-HT1BR binding using the radioligand [11C]AZ10419369 (BPND). 
  
RCFT/TCFT 1 
Delayed recall  
 
RCFT/TCFT 2 
Delayed recognition  
 
Verbal Fluency 
Letter production  
 
Verbal Fluency 
Category production  
 
 
TMT A  
 
 






























 P C P  P C P  P C P  P C P  P C P  P C P  P C 




-0.48   -
0.07  




0.05   -
0.25  
-0.26  -0.30   -0.33  0.20  




0.39   -
0.01  




-0.54   -
0.26  
-0.33  -0.53   -0.07  -
0.10  
SPC 0.58  0.58  -0.09   0.43  0.42  -0.04   -
0.19  
0.16  -0.19   0.06  -0.00  0.30   0.08  -
0.56  
-0.38   -
0.11  
-0.05  -0.45   -0.00  0.58  








0.23   -
0.25  
0.16  -0.20   -0.66  0.38  




-0.52   -
0.09  
0.06  -0.48   -
0.20  
0.35  0.25   -
0.17  
0.26  0.06   -0.42  -
0.18  




0.28   -
0.10  
-0.53  0.21   -
0.33  
0.31  -0.08   -
0.31  
0.64† -0.46   -0.68† 0.20  
DBS 0.69* 0.57  0.37   0.74* 0.83* 0.45   -
0.17  
0.02  -0.36   -
0.05  




0.16   -
0.36  
-0.44  -0.27   -0.44  0.20  
Note. RCFT=Rey´s Complex Figure Test, delayed recall and delayed recognition; TCFT=Taylor´s Complex Figure Test, delayed recall and delayed recognition; TMT A= Trailmaking test A; TMT 
B= Trailmaking test B; WAIS-III=Wechsler´s Adult Intelligence Scale, version III; P=patient group; C=control group; OFC=orbitofrontal cortex; ACC=anterior cingulate cortex; SPC=subgenual 











Figure 1. Scatter plot illustrating the association 
between the relative difference in letter production 
and binding potential (BPND) in ventral striatum. 
   
 
Figure 2. Scatter plot illustrating the association 
between relative difference in category production 
and binding potential (BPND) in amygdala. 


































Figure 3. Scatter plot illustrating the association between relative difference in Trailmaking Test 
B (TMT B) performance and binding potential (BPND) in dorsal brainstem (DBS), amygdala and 
hippocampus. 
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